Loading...
•
Sep 30, 2020
Royalty Pharma Q3 2020 Earnings Report
Royalty Pharma's third quarter results demonstrated strong growth and strategic advancements.
Key Takeaways
Royalty Pharma reported a strong third quarter with a 17% increase in net cash from operating activities and a 12% increase in adjusted cash receipts. The company also increased its 2020 guidance for adjusted cash receipts and announced $2.3 billion in new acquisitions for the year.
Net cash provided by operating activities increased by 17% to $509 million.
Adjusted Cash Receipts increased by 12% to $472 million.
Adjusted Cash Flow grew by 27% to $394 million.
$2.3 billion of new acquisitions were announced in 2020, including $1.1 billion in the third quarter.
Revenue by Segment
Forward Guidance
Royalty Pharma updated guidance for full-year 2020, expecting Adjusted Cash Receipts (non-GAAP) excluding new transactions announced after the date of this release to be $1,780 million to $1,800 million. They also expect that payments for operating and professional costs will be approximately 10% of Adjusted Cash Receipts in 2020.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...